Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Non-Current Liabilities: 2015-2024

Historic Total Non-Current Liabilities for Spyre Therapeutics (SYRE) over the last 9 years, with Dec 2024 value amounting to $54.1 million.

  • Spyre Therapeutics' Total Non-Current Liabilities fell 19.58% to $46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.3 million, marking a year-over-year decrease of 19.58%. This contributed to the annual value of $54.1 million for FY2024, which is 69.05% up from last year.
  • Per Spyre Therapeutics' latest filing, its Total Non-Current Liabilities stood at $54.1 million for FY2024, which was up 69.05% from $32.0 million recorded in FY2023.
  • Spyre Therapeutics' Total Non-Current Liabilities' 5-year high stood at $54.1 million during FY2024, with a 5-year trough of $21.6 million in FY2020.
  • Moreover, its 2-year median value for Total Non-Current Liabilities was $43.0 million (2023), whereas its average is $43.0 million.
  • In the last 5 years, Spyre Therapeutics' Total Non-Current Liabilities declined by 6.50% in 2020 and then skyrocketed by 69.05% in 2024.
  • Over the past 4 years, Spyre Therapeutics' Total Non-Current Liabilities (Yearly) stood at $21.6 million in 2020, then rose by 20.38% to $26.0 million in 2021, then reached $32.0 million in 2023, then surged by 69.05% to $54.1 million in 2024.